# UCLA UCLA Previously Published Works

# Title

Cortical Abnormalities Associated With Pediatric and Adult Obsessive-Compulsive Disorder: Findings From the ENIGMA Obsessive-Compulsive Disorder Working Group

Permalink https://escholarship.org/uc/item/498140w0

**Journal** American Journal of Psychiatry, 175(5)

**ISSN** 0002-953X

# Authors

Boedhoe, Premika SW Schmaal, Lianne Abe, Yoshinari <u>et al.</u>

**Publication Date** 

2018-05-01

# DOI

10.1176/appi.ajp.2017.17050485

Peer reviewed



# **HHS Public Access**

Author manuscript *Am J Psychiatry*. Author manuscript; available in PMC 2020 March 31.

Published in final edited form as:

Am J Psychiatry. 2018 May 01; 175(5): 453–462. doi:10.1176/appi.ajp.2017.17050485.

# Cortical abnormalities associated with pediatric and adult obsessive-compulsive disorder:

Findings from the ENIGMA Obsessive-Compulsive Disorder working group

A full list of authors and affiliations appears at the end of the article.

## Abstract

**Objective:** Brain imaging studies of structural abnormalities in OCD have yielded inconsistent results, partly due to limited statistical power, clinical heterogeneity, and methodological differences. Here, we perform meta- and mega-analyses comprising the largest study of cortical morphometry in OCD ever undertaken.

**Methods:** T1-weighted MRI scans of 1905 OCD patients and 1760 healthy controls from 27 sites worldwide were processed locally using FreeSurfer to assess cortical thickness and surface area. Effect sizes for differences between patients and controls, and associations with clinical characteristics, were calculated using linear regression models controlling for age, sex, site, and intracranial volume.

**Results:** In adult OCD patients versus controls, we found significantly lower surface area of the transverse temporal cortex and a thinner inferior parietal cortex. *Medicated* adult OCD patients also showed thinner cortices throughout the brain. In pediatric OCD patients versus controls, we found significantly thinner inferior and superior parietal cortices, but none of the regions analyzed showed significant differences in surface area. However, *medicated* pediatric OCD patients had lower surface area in frontal regions. Cohen's *d* effect sizes varied between -0.10 and -0.33.

**Conclusion**—The parietal cortex was consistently implicated both in adults and children with OCD. More widespread *cortical thickness* abnormalities were found in medicated adult OCD patients, and more pronounced *surface area* deficits (mainly in frontal regions) were found in medicated pediatric OCD patients. These cortical measures represent distinct morphological features and may be differentially affected during different stages of development and illness, and possibly moderated by disease profile and medication.

#### Keywords

OCD; MRI; FreeSurfer; Cortical Thickness; Surface Area

## Introduction

Disease models of obsessive-compulsive disorder (OCD) propose that abnormalities in the cortico-striato-thalamo-cortical (CSTC) circuits are key to the pathophysiology of OCD. More recent findings also implicate the involvement of fronto-limbic and fronto-parietal

<sup>\*</sup>See Full Consortium List excel file for the complete list of ENIGMA-OCD Working-Group members

regions in pediatric and adult OCD (1–3). An important limitation of brain imaging research is the typically small samples that limit sensitivity and presumably contributing to the lack of reproducibility and reliability (4). This issue may be partially addressed by the use of meta- and mega-analysis of multiple study samples. We therefore initiated the OCD working group within the Enhancing Neuro-Imaging Genetics through Meta-Analysis (ENIGMA) consortium (5) in which researchers around the world collaborate to boost statistical power, with the aim of elucidating brain abnormalities in OCD.

Recently, we performed meta- and mega-analyses on data from 3589 individuals and reported subcortical volume differences between OCD patients and healthy controls that were related to clinical characteristics. Distinct subcortical volume abnormalities were detected in adults and children with OCD. Adult OCD patients had significantly smaller hippocampal and larger pallidal volumes. The smaller hippocampal volume seemed to be driven by comorbid depression and an adult illness onset. The larger pallidal volume was more pronounced in adult OCD patients with a childhood illness onset. Children with OCD had larger thalamic volumes compared to control children (6).

With regard to the cortex, prior magnetic resonance imaging (MRI) studies consistently show abnormalities in dorsomedial prefrontal and anterior cingulate cortices (ACC) (7–10), findings that are supported by mega-analyses from the OCD Brain Imaging Consortium (11; 12). Also abnormalities in fronto-parietal and temporo-parietal regions have been reported (10; 12–14). Findings regarding the orbitofrontal cortex (OFC) (8; 11; 15) and operculum have been rather inconsistent (8; 10; 11; 13; 16). These inconsistencies may be partially explained by differences in processing protocols, limited statistical power, and clinical heterogeneity related to variation in disease profile and developmental stage.

Most of these studies were predominantly based on volumetric measures using voxel-based morphometry (VBM). Volumetric measures, however, depend on a combination of changes in gray matter thickness and surface area (17). Fewer studies have used surface-based methods to generate detailed maps of cortical thickness and surface area. These measures represent distinct features of cortical morphometry that are somewhat genetically independent and are driven by different neurobiological processes (18). Studying these properties independently will make it easier to interpret the cortical abnormalities reported in OCD in the context of the postulated neurodevelopmental basis for OCD (19) (Supplementary Information SI1).

Here we performed the largest coordinated worldwide study of cortical measures in patients with OCD compared to healthy controls. We extracted cortical thickness and surface area estimates of 1905 OCD patients and 1760 healthy controls, using harmonized data processing and analysis strategies across 27 sites. We also aimed to establish the potential modulating effects of demographic and clinical characteristics. Based on the prior literature, we expected lower cortical thickness in ACC, OFC, dorsomedial prefrontal cortex (dmPFC) and parietal regions, in OCD patients compared to healthy controls. In addition, we explored the cortical surface area profile in OCD.

#### Method

#### Samples

The ENIGMA-OCD working group includes 38 data sets from 27 international research institutes, with neuroimaging and clinical data from OCD patients and typically developing healthy control subjects (i.e., free of psychopathology), including both children and adults (participating sites are mapped in Supplementary Figure S1). Six (i.e. the entire OBIC sample) out of these 38 data sets were identical to those included in the OBIC mega-analyses using VBM (11) and vertex-based FreeSurfer (12). We defined adults as individuals aged 18 years and children as individuals aged <18 years. The split at the age of 18 followed from a natural selection of the age ranges used in these samples, as most samples used the age of 18 years as a cut-off for inclusion. Each sample's demographic and clinical characteristics are detailed in Supplementary Tables S1 and S2. In total, we analyzed data from 3665 subjects including 1905 OCD patients (407 children and 1498 adults) and 1760 control subjects (324 children and 1436 adults). All local institutional review boards permitted the use of measures extracted from the anonymized data for mega-analyses.

#### Image Acquisition and Processing

Structural T1-weighted MRI brain scans were acquired and processed locally. Image acquisition parameters for each site are given in Supplementary Table S3. All cortical parcellations were performed with the fully automated segmentation software FreeSurfer, version 5.3 (20), following standardized ENIGMA protocols to harmonize analyses and quality control procedures across multiple sites (see http://enigma.usc.edu/protocols/ imaging-protocols/). Segmentation of 68 (34 left and 34 right) cortical gray matter regions based on the Desikan-Killiany atlas (21) and two whole-hemisphere measures were visually inspected and statistically evaluated for outliers. Details on image exclusion criteria and quality control are presented in Supplementary Information SI1.

#### Statistical framework

We performed both a meta-analysis (i.e., using group statistics from the independent studies) and mega-analysis (i.e., pooling extracted measures from individual subjects across sites, while adjusting for site effects) to be consistent with our prior paper. In this manuscript we will focus on the mega-analysis. See Supplementary Information SI3 for methods, results and discussion of the meta-analysis.

We examined differences between OCD patients and controls within a mega-analytical framework by pooling the extracted cortical thickness and surface area measures from each site. Each of the 70 cortical regions of interest (68 regions and two whole-hemisphere average thickness or total surface area measures) served as the outcome measure and a binary indicator of diagnosis as the predictor of interest in multiple linear regression models. All cortical thickness models were adjusted for age and sex; cortical surface area models were corrected for intracranial volume (ICV, see Supplementary Information SI1), age, age<sup>2</sup>, sex, age-by-sex, and age<sup>2</sup>-by-sex, to account for any higher-order effects on cortical surface area of age and sex as well as head size, which do not appear to be detectable for cortical thickness measures (22). Additionally, all models were also adjusted for site, coded by using

dummy variables. Effect size estimates were calculated using the Cohen's *d* metric computed from the t-statistic of the diagnosis indicator variable from the regression models. Similarly, for models testing interactions (i.e., sex-by-diagnosis and age-by-diagnosis), a multiplicative predictor was the predictor of interest with the main effect of each predictor included in the model. The effect size was calculated using the same procedure.

To detect potentially different effects of disease with age, we performed all analyses separately for pediatric and adult participants. We performed stratified analyses comparing the medicated group and unmedicated group of OCD patients separately to controls and to each other. Likewise, stratified analyses were performed to investigate effect of comorbid major depressive disorder, comorbid anxiety disorders, and OCD symptom dimensions (using the Yale-Brown Obsessive Compulsive Scale [Y-BOCS] and the Children's Yale-Brown Obsessive Compulsive Scale [CY-BOCS] symptom checklist; see Supplementary Information SI2). To study the neurodevelopmental aspects of illness within the adult samples, we performed separate stratified analyses comparing childhood-onset OCD patients (onset <18 years) and adult-onset OCD patients (onset 18 years). Furthermore, we examined associations with age at onset, illness duration and illness severity (using the total severity score from the (C)Y-BOCS (23; 24)) as continuous variables. In these analyses, effect sizes were expressed as partial-correlation Pearson's r after removing nuisance variables (age, sex, site and ICV). Throughout the manuscript, we report *P*-values corrected for multiple comparisons using the Benjamini-Hochberg procedure to ensure a falsediscovery rate (FDR) limited at 5% for 70 cortical measures.

#### Results

An overview of the demographic and clinical characteristics of the pooled samples is provided in Table 1.

#### Mega-analysis

# Cortical thickness and surface area differences between OCD patients and controls

<u>Adults:</u> Lower cortical thickness was observed in adult OCD patients (N=1498) compared to controls (N=1436) in the bilateral inferior parietal cortex (Cohen's *d* effect size -0.14; Figure 1 and Supplementary Table S4). In all tables, regions are listed in order of effect size (strongest to weakest). A lower surface area was observed in the left transverse temporal cortex (Cohen's *d*-0.16; Supplementary Table S5 and Figure S2). None of the regions showed significant sex-by-diagnosis or age-by-diagnosis interaction effects.

<u>Children:</u> We found significantly thinner cortices in pediatric OCD patients (N=407) compared to controls (N=324) in bilateral superior parietal and left inferior parietal cortices (Figure 2) and left lateral occipital cortex (Cohen's *d* between -0.24 and -0.31; Supplementary Table S6). None of the regions analyzed showed significant differences in cortical surface area or evidence of sex-by-diagnosis or age-by-diagnosis interaction effects (Supplementary Table S7).

#### Influence of medication on cortical thickness and surface area

**Adults:** Left and right hemisphere cortical thickness was lower in medicated OCD patients (N=646) compared to controls (N=1436). Regionally, we found significantly thinner cortices in frontal, temporal, parietal and occipital regions of adult medicated OCD patients (Cohen's *d* between -0.10 and -0.26; Figure 3 and Supplementary Table S8a). We did not detect significant differences in cortical thickness in unmedicated OCD patients (N=831) compared to controls (Supplementary Table S8b). Medicated OCD patients compared to unmedicated patients showed lower cortical thickness in frontal, temporal and parietal regions (Cohen's *d* between -0.13 and -0.21; Supplementary Table S8c and Figure S3). Similar to the main group comparison, we found lower surface area of the left transverse temporal cortex in medicated OCD patients versus controls (Cohen's *d*-0.20; Supplementary Table S9a and Figure S4). We did not detect differences in surface area in unmedicated OCD patients directly (Supplementary Tables S9b–c).

**<u>Children:</u>** Compared to controls (N=324), medicated children with OCD (N=183) showed lower cortical thickness of the bilateral inferior parietal and superior parietal cortices and left lateral occipital cortex (Cohen's  $d \sim -0.31$ ; Supplementary Table S10a and Figure S5). We did not detect significant differences in cortical thickness in unmedicated pediatric OCD patients (N=222) compared to controls and when comparing medicated with unmedicated patients (Supplementary Tables S10b-c). More widespread surface area differences were detected when comparing medicated pediatric OCD patients to controls mainly in several frontal regions (Cohen's d between -0.27 and -0.33; Supplementary Table S11a and Figure 4). No differences in surface area were observed when comparing unmedicated patients to controls (Supplementary Table S11b). We did observe lower surface area of the right lingual (Cohen's d-0.34) and pericalcarine (Cohen's d-0.40) cortices in medicated compared to unmedicated pediatric OCD patients (Supplementary Table S11c and Figure 56).

**Influence of comorbidities on cortical thickness and surface area**—We did not detect any associations between cortical thickness or surface area and current comorbid depression or anxiety disorder in adults (respectively N=167 and N=224) or in children (respectively N=29 and N=132). These numbers, however, are too small because of the lack of systematic assessment of comorbidities in some samples and reflect an underestimation of comorbidity due to exclusion of comorbid cases in other samples. See Supplementary Information SI4 for full details.

#### Influence of symptom dimensions on cortical thickness and surface area

<u>Adults:</u> Regression analyses within OCD patients on symptom dimensions (N=1214) showed no associations between the presence of a particular symptom dimension and cortical thickness or surface area with any of the regions.

**<u>Children:</u>** Pediatric OCD patients with ordering and symmetry symptoms (N=181) showed a higher surface area of the left cuneus (Cohen's *d*0.49; Supplementary Table S20 and Figure S14). None of the regions analyzed showed significant differences in cortical thickness or evidence of associations with the other symptom dimensions.

Influence of age at onset and illness duration on cortical thickness and surface area—Adult OCD patients with an adult illness onset (N=775) compared to controls (N=1436) showed thinner cortices in left and right hemisphere overall. Regionally, we observed thinner cortices in frontal and temporal regions of adult-onset patients (Cohen's *d* between -0.11 and -0.16; Supplementary Table S21a and Figure S15). We also found lower surface area of the left transverse temporal cortex (Cohen's *d*-0.17) and the left pars opercularis (Cohen's *d*-0.14) in adult OCD patients with an adult illness onset (Supplementary Table S22a and Figure S16). We did not detect significant differences in cortical thickness or surface area in adult OCD patients with a childhood illness onset (N=646) compared to controls or when comparing adult-onset and childhood-onset patients directly (Supplementary Tables S21b–c and Supplementary Tables S22b–c).

Furthermore, we did not observe any significant linear (Supplementary Tables S23–S26) or quadratic (Supplementary Tables S37–S40) associations between age at onset or illness duration as continuous variables and cortical thickness or surface area changes in the adult (N=1419) or pediatric (N=708) OCD groups.

Association between illness severity and cortical thickness and surface area —We did not detect any significant linear (Supplementary Tables S27–S28) or quadratic (Supplementary Tables S41–S42) associations in either the adult (N=1453) or the pediatric (N=404) OCD patients between illness severity ([C]Y-BOCS) and cortical thickness or surface area.

#### Meta-analysis

Decreased cortical thickness of the inferior parietal cortex was present in adult patients with OCD compared to healthy controls, but at a less stringent significance threshold (Cohen's  $d \approx -0.14$ ; p <0.01, uncorrected). The meta-analysis did show significant widespread effects of medication on cortical thickness and a lower surface area of the transverse temporal cortex in adult OCD patients. The pediatric meta-analysis, also on a less stringent significance threshold (Cohen's  $d \approx -0.31$ ; p <0.05, uncorrected), showed decreased cortical thickness of the inferior and superior parietal cortex in children with OCD. In addition, field strength did not significantly explain the effect size estimates of cortical thickness or surface area differences in adult and pediatric OCD patients compared to controls (Supplementary Information SI3)

#### Discussion

#### **Cortical thickness**

This is the largest neuroimaging study conducted on cortical measures in OCD to date. We found that the parietal cortex was consistently implicated both in adult and pediatric OCD, which is consistent with prior VBM and FreeSurfer studies (12; 25). Lower cortical thickness of the inferior parietal cortex in adult OCD patients compared to controls is in accordance with results reported by Kuhn *et al.* (10) and the OBIC consortium (12). Lower cortical thickness of the inferior and superior parietal cortex in children with OCD is a novel finding. The only other study of cortical thickness in pediatric OCD found lower cortical

thickness of another parietal region, the supramarginal gyrus (29). Other imaging studies have reported lower gray matter volume in the parietal lobe, especially in the angular gyrus of the inferior parietal lobe in children and adults with OCD (25; 30).

In contrast to previous mega-analyses from the OBIC consortium, we did not find cortical thickness abnormalities in the OFC, ACC, or dmPFC. Six (i.e. the entire OBIC sample) out of our 38 data sets were identical to those included in the OBIC mega-analysis. Apart from a much larger sample size including samples from more different countries, no discrepancies between demographic and clinical characteristics could be found between this sample and the OBIC sample. Thus these inconsistencies are likely to reflect differences in analysis methods and the overall sample size. While FreeSurfer measures thickness and surface area separately, it segments whole structures based on probabilistic information from a predefined atlas (20), compared to VBM's voxel-wise registration (26). Mainly global or regional differences in structure can be inferred from these atlas-based FreeSurfer analyses, as opposed to local morphology as with VBM. Moreover, the FreeSurfer mega-analysis of the OBIC consortium (12) was conducted using vertex-based analyses rather than the atlasbased approach we used in the current study. It is thus possible that certain abnormalities on vertex level are not detectable when averaging data across whole regions (27). Notably, the OBIC sample included only 1.5T scans and was processed using an older version of FreeSurfer V4.5. Future research using higher resolution parcellation (e.g., (28)) is necessary to validate our results.

In the present study we had sufficient statistical power to detect subtle (Cohen's d, -0.15 to -0.31) cortical abnormalities in OCD (Supplemental Information SI5). Large-scale studies such as ours are well powered to distinguish consistent, generalizable findings from false positives. Structural MRI provides a crude and indirect measure of putative alterations at the molecular level, but these subtle abnormalities in the parietal cortex may still be relevant from a pathophysiological perspective (31). These results provide insight into what systems are affected, and promote further research to evaluate specific pathways implicated in the pathophysiology of OCD.

Neuroimaging studies of normal brain maturation demonstrate a continuous increase in parietal thickness reaching peak values around age 12, followed by a steady decrease over subsequent decades (32). In terms of neurodevelopmental abnormalities, our results may be cautiously interpreted as evidence for a relationship between the expression of OCD and disturbances in factors influencing radial cortical expansion, which influences gray matter thickness rather than factors influencing the tangential expansion that determines the overall surface area (33). In this context, our results could indicate an altered cortical maturation in OCD resulting in a thinner parietal cortex in early childhood, persisting into adulthood, although further confirmatory work using longitudinal samples is needed.

Cognitive studies in OCD suggest that the parietal cortex plays a significant role in accounting for the cognitive deficits seen in OCD patients. Parietal lobe activation may be related to attention, set shifting, planning and response inhibition, which are also reported to be impaired in OCD patients (34) and reflect a lack of cognitive flexibility that may be related to the repetitive nature of OCD symptoms and behaviors. The inferior parietal cortex

is an important node in both the fronto-parietal network and the default mode network. Several studies reported altered connectivity within these networks in patients with OCD (35–37). The phenomenology of the disorder is consistent with the idea of a disrupted relationship between ongoing internal thought and external information, in that patients often excessively focus on internally generated fears that are inconsistent with evidence present in the external environment (38).

We reported lower cortical thickness of numerous regions throughout the brain of medicated adult OCD patients. These medication effects partially overlap with prior research (12). Although these findings need to be interpreted with caution, it has been suggested that antidepressants might modulate plasticity in the brain (39). Additionally, post-hoc analyses suggest that these medication effects are strongest in those patients taking antidepressants with adjuvant antipsychotics (Supplementary Tables S36a-c and Supplementary Info SI4). Alternatively, those patients taking medication could represent a more clinically severe cohort that manifests these morphometric abnormalities. Results may have been confounded by a higher illness severity and a higher percentage of comorbid depression of the medicated adult OCD group (Supplementary Table S35). However, results of post-hoc analyses comparing the most severe (YBOCS>30) unmedicated OCD patients to controls did not resemble the same pattern of medication effects. Nevertheless, the cortical abnormalities in currently medicated OCD patients could reflect persistent abnormalities related to increased OCD severity before treatment. In addition, medication effects persisted after adding a covariate correcting for illness severity (data not shown). The lack of association between severity according to the (C)Y-BOCS and cortical measures could be due to medication reducing the symptom severity. Additionally, current symptom severity might not be optimal to capture the long-term disease severity.

With regard to retrospectively ascertained age at onset in adult patients, the lack of inferior parietal abnormalities in the adult sample with childhood onset might be explained by insufficient power. When looking at the effect sizes, decreased cortical thickness of the inferior parietal cortex was present in adult patients with a childhood disease onset compared to healthy controls, but at a less stringent significance threshold. The effect size was even slightly larger than the effect size of the main group comparison suggesting a power issue, rather than a lack of inferior parietal abnormalities. In contrast, adult illness onset was associated with widespread thinner cortices. The adult-onset group is older than the childhood-onset group, but also has a higher percentage of medicated patients. Post hoc analyses showed that these effects mostly disappear when correcting for medication status suggesting that these findings are mainly driven by medication.

Cortical structural deficits were not associated with comorbid depression or anxiety. The effect sizes of these small sub-groups with comorbid anxiety or depression indicate insufficient statistical power to address this issue with certainty. From a clinical point of view comorbid Tourette's syndrome and attention-hyperactivity-deficit disorder are more relevant to study in children with OCD. Because of the lack of systematic clinical investigation of comorbidities we were unable to investigate this. Common comorbidities may be more aptly termed interacting variables, as they interact in complex ways. Therefore,

excluding comorbid conditions will ignore complex interactions that are often integral to the disorder.

#### Surface area

The transverse temporal cortex surface area deficit was consistent across analyses in adult OCD. This region belongs to the primary auditory cortex and has not been implicated in OCD pathophysiology before. Lower cortical thickness and lower volume of this region have been associated with auditory hallucinations in schizophrenia (40). Prior approaches to detect structural alteration in this region may have been hampered by small samples or the modest sensitivity of conventional volumetric approaches. The advantage of high statistical power allows us to examine abnormalities throughout the brain without the need to prespecify regions of interest and thus identify new regions putatively associated with the disorder. Further research is necessary understand the involvement of the transverse temporal cortex in OCD.

Medicated children with OCD had smaller left and right hemisphere total surface area, reflecting a diffuse pattern of frontal surface area deficits. These findings cannot be explained by differences in illness severity, comorbidity or age at onset (Supplementary Table S35). This may indicate delayed cortical maturation, although longitudinal studies are needed to prove that. The surface area of these frontal regions matures over a more prolonged time course during adolescence (41) and may be especially prone to a maturational delay in pediatric OCD, possibly affected by medication status. Such delayed maturation may alter functional connections with other regions through decreases in growth and branching of dendritic trees and the number of synapses associated with gray matter volume (42), which may persist into adult OCD even if surface area abnormalize when transitioning into adulthood. The absence of cortical surface area abnormalities in the adult OCD patients with a childhood-onset could indicate such normalization.

#### Limitations

When combining existing data across samples worldwide, data collection protocols were not prospectively harmonized. Imaging acquisition protocols and clinical assessments therefore differed across studies, which limits analysis of sources of heterogeneity. As another limitation we note that the T1-weighted scans were not collected with direct measures of head motion, which might have introduced potential motion-induced bias in cortical measures (43).

In addition, FreeSurfer measurements may benefit from manual edits if they are made consistently across all scans. Although we had an extensive standardized protocol for quality checking, the individual sites did not perform manual editing, as this could have resulted in increased variation in the data across sites due to high number of sites involved.

We reported widespread medication effects both in adults and children with OCD. However, the current study did not allow a reliable investigation of medication effects because of its cross-sectional design and lack of detailed information on history, duration, type, and dosage of psychotropic treatment. We therefore must interpret our results with caution and cannot make any premature conclusions about the effect of anti-OCD medication. Further efforts,

e.g. intervention studies with comparisons before and after medication, are required to draw valid conclusions on the impact of medication use on cortical structure.

Several studies using a symptom dimensional approach suggest that symptom dimensions may be mediated by partially distinct neural systems (44; 45). Except for the association between a higher surface area of the left cuneus and ordering/symmetry dimension in children, we did not detect thickness or surface area effects of the other symptom dimensions in children and adults. An explanation may be that symptom subtype differences are more focal and remain undetected in this atlas-based analysis. On the other hand, variance in use of instruments across the participating sites might have led to suboptimal harmonization of the symptom dimensions in our study. During harmonization, we defined symptom dimensions in a binary manner as absent or present for each participant based on the (C)Y-BOCS symptom checklist, whereas prior studies have correlated the dimension scores with cortical measures.

As a minor limitation, we note that followed from a natural selection of study samples we split the data in adults ( 18 years) and children (< 18 years), which might not be the optimal cut-off related to the onset and evolution of OCD (46; 47) In addition, the pediatric sample represents a wide age range, including puberty. We did not have enough data on pubertal stage to take pubertal development into account. Given the role of hormonal influence on cortical structures this will be useful to pursue in future research.

#### Conclusion

The parietal cortex was implicated in both adult and pediatric OCD. These results support the hypothesis that the pathophysiology of OCD cannot be solely explained by alterations of the classical CSTC regions and emphasize the importance of parietal regions. Widespread cortical thickness abnormalities were found in medicated adult OCD patients, while more pronounced surface area deficits were found in medicated pediatric OCD patients. Cortical thickness and surface area represent distinct features of the cortex and may be differentially affected by OCD and possibly moderated by medication status. Further work, using longitudinal designs, and incorporating genetic and environmental variables, will be useful in understanding the precise mechanisms underlying the structural abnormalities preceding the onset of the illness and occurring during the course of the illness.

#### **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

#### Authors

Premika S.W. Boedhoe, M.Sc.<sup>1,2,3</sup>, Lianne Schmaal, Ph.D.<sup>1,3,4,5</sup>, Yoshinari Abe, M.D.<sup>6</sup>, Pino Alonso, M.D., Ph.D.<sup>7,8,9</sup>, Stephanie H. Ameis, M.D. M.Sc.<sup>10,11</sup>, Alan Anticevic, Ph.D.<sup>12</sup>, Paul D. Arnold, M.D., Ph.D.<sup>13,14</sup>, Marcelo C. Batistuzzo, Ph.D.<sup>15</sup>, Francesco Benedetti, M.D.<sup>16</sup>, Jan C. Beucke, Ph.D.<sup>17</sup>, Irene Bollettini, Ph.D.<sup>16</sup>, Anushree Bose, M.A.<sup>18</sup>, Silvia Brem, Ph.D.<sup>19</sup>, Anna Calvo, M.Sc.<sup>20</sup>, Rosa Calvo,

M.D., Ph.D.<sup>21,8</sup>, Yuqi Cheng, Ph.D.<sup>22</sup>, Kang Ik K. Cho, Ph.D.<sup>23</sup>, Valentina Ciullo. Ph.D.<sup>24</sup>, Sara Dallaspezia, M.D.<sup>16</sup>, Damiaan Denys, M.D., Ph.D.<sup>3,25,26</sup>, Jamie D. Feusner, M.D.<sup>27</sup>, Kate D. Fitzgerald, M.D.<sup>28</sup>, Jean-Paul Fouche, Ph.D.<sup>29</sup>, Egill A. Fridgeirsson, M.Sc.<sup>3,25</sup>, Patricia Gruner, Ph.D.<sup>12</sup>, Gregory L. Hanna, M.D.<sup>28</sup>, Derrek P. Hibar, Ph.D.<sup>31</sup>, Marcelo Q. Hoexter, M.D., Ph.D.<sup>14</sup>, Hao Hu, Ph.D.<sup>32</sup>, Chaim Huyser, M.D., Ph.D.<sup>33,34</sup>, Neda Jahanshad, Ph.D.<sup>31</sup>, Anthony James, M.D.<sup>35</sup>, Norbert Kathmann, Ph.D.<sup>17</sup>, Christian Kaufmann, Ph.D.<sup>17</sup>, Kathrin Koch, Ph.D.<sup>36,37</sup>, Jun Soo Kwon, M.D., Ph.D.<sup>38,39</sup>, Luisa Lazaro, M.D., Ph.D.<sup>21,40,41,8</sup>, Christine Lochner, Ph.D.<sup>42</sup>, Rachel Marsh, Ph.D.<sup>43,44</sup>, Ignacio Martínez-Zalacaín, M.Sc.<sup>7</sup>, David Mataix-Cols, Ph.D.<sup>45</sup>, José M. Menchón, M.D., Ph.D.<sup>7,8,9</sup>, Luciano Minuzzii. M.D., Ph.D.<sup>46</sup>, Astrid Morer, M.D., Ph.D.<sup>21,40,8</sup>, Takashi Nakamae, M.D., Ph.D.<sup>6</sup>, Tomohiro Nakao, M.D., Ph.D.<sup>47</sup>, Janardhanan C. Narayanaswamy, M.D.<sup>18</sup>, Seiji Nishida, M.D., Ph.D.<sup>6</sup>, Erika Nurmi, M.D., Ph.D.<sup>27</sup>, Joseph O'neill, Ph.D.<sup>27</sup>, John Piacentini, Ph.D.<sup>27</sup>, Fabrizio Piras, Ph.D.<sup>24,48</sup>, Federica Piras, Ph.D.<sup>24</sup>, Y.C. Janardhan Reddy, M.D.<sup>18</sup>, Tim J. Reess, M.A.<sup>36,37</sup>, Yuki Sakai, M.D., Ph.D.<sup>49,6</sup>, Joao R. Sato, Ph.D.<sup>50</sup>, H. Blair Simpson, M.D., Ph.D.<sup>43,51</sup>, Noam Soreni, M.D.<sup>52</sup>, Carles Soriano-Mas, Ph.D.<sup>7,8,53</sup>, Gianfranco Spalletta, M.D., Ph.D.<sup>24,54</sup>, Michael C. Stevens, Ph.D.<sup>55,56</sup>, Philip R. Szeszko, Ph.D.<sup>57,58</sup>, David F. Tolin, Ph.D.<sup>59,55</sup>, Guido A. van Wingen, Ph.D.<sup>3,25</sup>, Ganesan Venkatasubramanian, M.D., Ph.D.<sup>18</sup>, Susanne Walitza, M.D., M.Sc.<sup>19</sup>, Zhen Wang, M.D., Ph.D.<sup>32,60</sup>, Je-Yeon Yun, M.D., Ph.D.<sup>30,61</sup>, ENIGMA-OCD Working-Group<sup>\*</sup>, Paul M. Thompson, Ph.D.<sup>31</sup>, Dan J. Stein, M.D., Ph.D.<sup>29</sup>, Odile A. van den Heuvel, M.D., Ph.D.<sup>1,2,3</sup>

#### Affiliations

<sup>1</sup>Department of Psychiatry, VU university medical center, Amsterdam, The Netherlands <sup>2</sup>Department of Anatomy & Neurosciences, VU university medical center, Amsterdam, The Netherlands <sup>3</sup>Amsterdam Neuroscience, Amsterdam, The Netherlands <sup>4</sup>Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia <sup>5</sup>Centre for Youth Mental Health, The University of Melbourne, Melbourne, VIC, Australia <sup>6</sup>Department of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan <sup>7</sup>Department of Psychiatry, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain <sup>8</sup>Centro de Investigación Biomèdica en Red de Salud Mental (CIBERSAM), Barcelona, Spain <sup>9</sup>Department of Clinical Sciences, University of Barcelona, Spain <sup>10</sup>The Margaret and Wallace McCain Centre for Child, Youth & Family Mental Health, Campbell Family Mental Health Research Institute, The Centre for Addiction and Mental Health, Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Canada <sup>11</sup>Centre for Brain and Mental Health, The Hospital for Sick Children, Toronto, Canada <sup>12</sup>Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, U.S.A. <sup>13</sup>Mathison Centre for Mental Health Research & Education, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada <sup>14</sup>Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada <sup>15</sup>Department of Psychiatry, Institute of Psychiatry, University of São Paulo School of Medicine, São

Paulo, Brazil <sup>16</sup>Psychiatry and Clinical Psychobiology, Division of Neuroscience, Scientific Institute Ospedale San Raffaele, Milano, Italy <sup>17</sup>Department of Psychology, Humboldt-Universität zu Berlin, Berlin, Germany <sup>18</sup>Obsessive-Compulsive Disorder (OCD) Clinic Department of Psychiatry National Institute of Mental Health & Neurosciences, Bangalore, India <sup>19</sup>Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Zurich, Switzerland <sup>20</sup>Magnetic Resonance Image Core Facility, IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Barcelona, Spain <sup>21</sup>Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clínic Universitari, Barcelona, Spain <sup>22</sup>Department of Psychiatry, First Affiliated Hospital of Kunming Medical University, Kunming, China <sup>23</sup>Institute of Human Behavioral Medicine, SNU-MRC, Seoul, Republic of Korea <sup>24</sup>Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy <sup>25</sup>Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands <sup>26</sup>Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands <sup>27</sup>Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, U.S.A. <sup>28</sup>Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, U.S.A <sup>29</sup>Department of Psychiatry, University of Cape Town, Cape Town, South Africa <sup>30</sup>Yeongeon Student Support Center, Seoul National University College of Medicine, Seoul, Republic of Korea <sup>31</sup>Imaging Genetics Center, Mark and Mary Stevens Neuroimaging & Informatics Institute, Keck School of Medicine of the University of Southern California, Marina del Rey, CA, U.S.A. <sup>32</sup>Shanghai Mental Health Center Shanghai Jiao Tong University School of Medicine, PR China <sup>33</sup>De Bascule, Academic Center for Child and Adolescent Psychiatry, Amsterdam, the Netherlands <sup>34</sup>Department of Child and Adolescent Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands <sup>35</sup>Department of Psychiatry, Oxford University, Oxford, U.K. <sup>36</sup>Department of Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Germany <sup>37</sup>TUM-Neuroimaging Center (TUM-NIC) of Klinikum rechts der Isar, Technische Universität München, Germany <sup>38</sup>Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea <sup>39</sup>Department of Brain & Cognitive Sciences, Seoul National University College of Natural Sciences, Seoul, Republic of Korea <sup>40</sup>Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain <sup>41</sup>Department of Medicine, University of Barcelona, Barcelona, Spain <sup>42</sup>SU/UCT MRC Unit on Anxiety & Stress Disorders, Department of Psychiatry, University of Stellenbosch, South Africa <sup>43</sup>Columbia University Medical College, Columbia University, New York, NY, U.S.A. <sup>44</sup>The New York State Psychiatric Institute, New York, NY, U.S.A. <sup>45</sup>Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden <sup>46</sup>Mood Disorders Clinic, St. Joseph's HealthCare, Hamilton, Ontario, Canada <sup>47</sup>Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan <sup>48</sup>Centro Fermi - Museo Storico della Fisica e Centro Studi e Ricerche "Enrico Fermi" <sup>49</sup>ATR

Brain Information Communication Research Laboratory Group, Kyoto, Japan <sup>50</sup>Center for Mathematics, Computing and Cognition, Universidade Federal do ABC, Santo Andre, Brazil <sup>51</sup>Center for OCD and Related Disorders, New York State Psychiatric Institute, New York, NY, U.S.A. <sup>52</sup>Anxiety Treatment and Research Center, St. Joseph's HealthCare, Hamilton, Ontario, Canada <sup>53</sup>Department of Psychobiology and Methodology of Health Sciences, Universitat Autònoma de Barcelona, Spain <sup>54</sup>Beth K. and Stuart C. Yudofsky Division of Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA <sup>55</sup>Yale University School of Medicine, New Haven, Connecticut, U.S.A. <sup>56</sup>Clinical Neuroscience and Development Laboratory, Olin Neuropsychiatry Research Center, Hartford, Connecticut, U.S.A. <sup>57</sup>Icahn School of Medicine at Mount Sinai, New York, U.S.A. <sup>58</sup>James J. Peters VA Medical Center, Bronx, New York, U.S.A. <sup>60</sup>Shanghai Key Laboratory of Psychotic Disorders, PR China <sup>61</sup>Seoul National University Hospital, Seoul, Republic of Korea

## **Disclosures and acknowledgements:**

All authors have no conflicts of interest related to this study. Dan J. Stein has received research grants and/or consultancy honoraria from AMBRF, Biocodex, Cipla, Lundbeck, National Responsible Gambling Foundation, Novartis, Servier, and Sun in the past 3 years.

The ENIGMA-Obsessive Compulsive Disorder Working-Group gratefully acknowledges support from the NIH BD2K award U54 EB020403-02 (PI: Dr. Thompson) and Neuroscience Amsterdam, IPB-grant to Dr. Schmaal & Dr. van den Heuvel. Supported by the Hartmann Muller Foundation (No. 1460 to Dr. Brem); the International Obsessive-Compulsive Disorder Foundation (IOCDF) Research Award to Dr. Gruner; the Dutch Organization for Scientific Research (NWO) (grants 912-02-050, 907-00-012, 940-37-018, and 916.86.038); the Netherlands Society for Scientific Research (NWO-ZonMw VENI grant 916.86.036 to Dr. van den Heuvel; NWO-ZonMw AGIKO stipend 920-03-542 to Dr. de Vries), a NARSAD Young Investigators Award to Dr. van den Heuvel, and the Netherlands Brain Foundation (2010(1)-50 to Dr. van den Heuvel); Oxfordshire Health Services Research Committee (OHSRC) (Dr. Anthony James); the Deutsche Forschungsgemeinschaft (DFG) (KO 3744/2-1 to Dr. Koch); the Marató TV3 Foundation grants 01/2010 and 091710 to Dr. Lazaro; the Wellcome Trust and a pump priming grant from the South London and Maudsley Trust, London, UK (Project grant no. 064846) to Dr. Mataix-Cols; the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT KAKENHI No. 26461753 to Dr. Nakamae); International OCD Foundation Research Award 20153694 and an UCLA Clinical and Translational Science Institute Award (to Dr. Nurmi); National Institutes of Mental Health grant R01MH081864 (to Drs. O'Neill and Piacentini) and grant R01MH085900 (to Drs. O'Neill and Feusner); the Government of India grants to Prof. Y.C. Janardhan Reddy (SR/S0/HS/0016/2011) and Dr. Janardhanan C. Narayanaswamy (DST INSPIRE faculty grant -IFA12-LSBM-26) of the Department of Science and Technology; the Government of India grants to Prof. Y.C. Janardhan Reddy (No.BT/PR13334/Med/30/259/2009) and Dr. Janardhanan C. Narayanaswamy (BT/06/IYBA/2012) of the Department of Biotechnology; the Wellcome-DBT India Alliance grant to Dr. Ganesan Venkatasubramanian (500236/Z/11/Z); the Carlos III Health Institute (CP10/00604, PI13/00918, PI13/01958, PI14/00413/PI040829); FEDER funds/European Regional Development Fund (ERDF), AGAUR (2014 SGR 1672 and 2014 SGR 489); a "Miguel Servet" contract (CP10/00604) from the Carlos III Health Institute to Dr. Soriano-Mas; the Italian Ministry of Health (RC10-11-12-13-14-15A to Dr. Spalletta); the Swiss National Science Foundation (No. 320030\_130237 to Dr. Walitza); and the Netherlands Organization for Scientific Research (NWO VIDI 917-15-318 to Dr. van Wingen).

Further we wish to acknowledge Nerisa Banaj, Ph.D., Silvio Conte, Sergio Hernandez B.A., Yu Jin Ressal and Alice Quinton.

### References

- van den Heuvel OA, van Wingen G, Soriano-Mas C, Alonso P, Chamberlain SR, Nakamae T, Denys D, Goudriaan AE, Veltman DJ: Brain circuitry of compulsivity. Eur. Neuropsychopharmacol. 2016; 26:810–827 [PubMed: 26711687]
- Milad MR, Rauch SL: Obsessive-compulsive disorder: Beyond segregated cortico-striatal pathways. Trends Cogn. Sci. 2012; 16:43–51 [PubMed: 22138231]
- Piras F, Piras F, Chiapponi C, Girardi P, Caltagirone C, Spalletta G: Widespread structural brain changes in OCD: A systematic review of voxel-based morphometry studies. Cortex 2015; 62:89– 108 [PubMed: 23582297]
- Button KS, Ioannidis JP a, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, Munafò MR: Power failure: why small sample size undermines the reliability of neuroscience. Nat. Rev. Neurosci. 2013; 14:365–76 [PubMed: 23571845]
- 5. Thompson PM, Andreassen OA, Arias-Vasquez A, Bearden CE, Boedhoe PS, Brouwer RM, Buckner RL, Buitelaar JK, Bulaeva KB, Cannon DM, Cohen RA, Conrod PJ, Dale AM, Deary IJ, Dennis EL, de Reus M a., Desrivieres S, Dima D, Donohoe G, Fisher SE, Fouche J-P, Francks C, Frangou S, Franke B, Ganjgahi H, Garavan H, Glahn DC, Grabe HJ, Guadalupe T, Gutman B a., Hashimoto R, Hibar DP, Holland D, Hoogman M, Pol HEH, Hosten N, Jahanshad N, Kelly S, Kochunov P, Kremen WS, Lee PH, Mackey S, Martin NG, Mazoyer B, McDonald C, Medland SE, Morey RA, Nichols TE, Paus T, Pausova Z, Schmaal L, Schumann G, Shen L, Sisodiya SM, Smit DJ a., Smoller JW, Stein DJ, Stein JL, Toro R, Turner J a., van den Heuvel M, van den Heuvel O a., van Erp TGM, van Rooij D, Veltman DJ, Walter H, Wang Y, Wardlaw JM, Whelan CD, Wright MJ, Ye J: ENIGMA and the Individual: Predicting Factors that Affect the Brain in 35 Countries Worldwide. Neuroimage 2017; 145;389–408 [PubMed: 26658930]
- 6. Boedhoe PSW, Schmaal L, Abe Y, Ameis SH, Arnold PD, Batistuzzo MC, Benedetti F, Beucke JC, Bollettini I, Bose A, Brem S, Calvo A, Cheng Y, Cho KIK, Dallaspezia S, Denys D, Fitzgerald KD, Fouche J-P, Giménez M, Gruner P, Hanna GL, Hibar DP, Hoexter MQ, Hu H, Huyser C, Ikari K, Jahanshad N, Kathmann N, Kaufmann C, Koch K, Kwon JS, Lazaro L, Liu Y, Lochner C, Marsh R, Martínez-Zalacaín I, Mataix-Cols D, Menchón JM, Minuzzii L, Nakamae T, Nakao T, Narayanaswamy JC, Piras F, Piras F, Pittenger C, Reddy YCJ, Sato JR, Simpson HB, Soreni N, Soriano-Mas C, Spalletta G, Stevens MC, Szeszko PR, Tolin DF, Venkatasubramanian G, Walitza S, Wang Z, van Wingen GA, Xu J, Xu X, Yun J-Y, Zhao Q, Thompson PM, Stein DJ, van den Heuvel OA, Heuvel OA van den: Distinct Subcortical Volume Alterations in Pediatric and Adult OCD: A Worldwide Meta- and Mega-Analysis. Am. J. Psychiatry 2017; 174:60–70 [PubMed: 27609241]
- Radua J, Mataix-Cols D: Voxel-wise meta-analysis of grey matter changes in obsessive-compulsive disorder. Br. J. Psychiatry 2009; 195:393–402 [PubMed: 19880927]
- Rotge J-Y, Langbour N, Guehl D, Bioulac B, Jaafari N, Allard M, Aouizerate B, Burbaud P: Gray matter alterations in obsessive-compulsive disorder: an anatomic likelihood estimation metaanalysis. Neuropsychopharmacology 2010; 35:686–691 [PubMed: 19890260]
- Venkatasubramanian G, Zutshi A, Jindal S, Srikanth SG, Kovoor JME, Kumar JK, Janardhan Reddy YC: Comprehensive evaluation of cortical structure abnormalities in drug-naive, adult patients with obsessive-compulsive disorder: A surface-based morphometry study. J. Psychiatr. Res. 2012; 46:1161–1168 [PubMed: 22770508]
- Kuhn S, Kaufmann C, Simon D, Endrass T, Gallinat J, Kathmann N: Reduced thickness of anterior cingulate cortex in obsessive-compulsive disorder. Cortex 2013; 49:2178–2185 [PubMed: 23067727]
- 11. de Wit SJ, Alonso P, Schweren L, Mataix-Cols D, Lochner C, Menchón JM, Stein DJ, Fouche JP, Soriano-Mas C, Sato JR, Hoexter MQ, Denys D, Nakamae T, Nishida S, Kwon JS, Jang JH, Busatto GF, Cardoner N, Cath DC, Fukui K, Jung WH, Kim SN, Miguel EC, Narumoto J, Phillips ML, Pujol J, Remijnse PL, Sakai Y, Shin NY, Yamada K, Veltman DJ, Van Den Heuvel OA.: Multicenter voxelbased morphometry mega-analysis of structural brain scans in obsessive-compulsive disorder. Am. J. Psychiatry 2014; 171:340–349 [PubMed: 24220667]
- 12. Fouche J-P, du Plessis S, Hattingh C, Roos A, Lochner C, Soriano-Mas C, Sato JR, Nakamae T, Nishida S, Kwon JS, Jung WH, Mataix-Cols D, Hoexter MQ, Alonso P, OCD Brain Imaging Consortium, de Wit SJ, Veltman DJ, Stein DJ, van den Heuvel OA: Cortical thickness in


obsessive-compulsive disorder: multisite mega-analysis of 780 brain scans from six centres. Br. J. Psychiatry 2017; 210:67–74 [PubMed: 27198485]

- Nakamae T, Narumoto J, Sakai Y, Nishida S, Yamada K, Kubota M, Miyata J, Fukui K: Reduced cortical thickness in non-medicated patients with obsessive-compulsive disorder. Prog. NeuroPsychopharmacology Biol. Psychiatry 2012; 37:90–95
- 14. Fan Q, Palaniyappan L, Tan L, Wang J, Wang X, Li C, Zhang T, Jiang K, Xiao Z, Liddle PF: Surface anatomical profile of the cerebral cortex in obsessive–compulsive disorder: a study of cortical thickness, folding and surface area. Psychol. Med. 2013; 43:1081–1091 [PubMed: 22935427]
- Radua J, van den Heuvel O a, Surguladze S, Mataix-Cols D: Meta-analytical comparison of voxelbased morphometry studies in obsessive-compulsive disorder vs other anxiety disorders. Arch. Gen. Psychiatry 2010; 67:701–711 [PubMed: 20603451]
- Narayan VM, Narr KL, Philips OR, Thompson PM, Toga AW, Szeszko PR: Greater regional cortical gray matter thickness in obsessive-compulsive disorder. Neuroreport 2008; 19:1551–1555 [PubMed: 18797315]
- Hutton C, Draganski B, Ashburner J, Weiskopf N: A comparison between voxel-based cortical thickness and voxel-based morphometry in normal aging. Neuroimage 2009; 48:371–380 [PubMed: 19559801]
- Winkler AM, Kochunov P, Fox PT, Duggirala R, Almasy L, Blangero J, Glahn DC: Heritability of volume, surface area and thickness for anatomically defined cortical brain regions estimated in a large extended pedigree. Neuroimage 2009; 47:S162
- Rosenberg DR, Keshavan MS: Toward a neurodevelopmental model of obsessive-compulsive disorder. Biol. Psychiatry 1998; 43:623–640 [PubMed: 9582996]
- 20. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, Van Der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM: Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron 2002; 33:341–355 [PubMed: 11832223]
- 21. Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ: An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006; 31:968–980 [PubMed: 16530430]
- Westlye LT, Walhovd KB, Dale AM, Bjørnerud A, Due-Tønnessen P, Engvig A, Grydeland H, Tamnes CK, Østby Y, Fjell AM: Differentiating maturational and aging-related changes of the cerebral cortex by use of thickness and signal intensity. Neuroimage 2010; 52:172–185 [PubMed: 20347997]
- Scahill L, Riddle M a., McSWIGGIN-HARDIN M, Ort SI, King R a., Goodman WK, Cicchetti D, Leckman JF: Children's Yale-Brown Obsessive Compulsive Scale: Reliability and Validity. J. Am. Acad. Child Adolesc. Psychiatry 1997; 36:844–852 [PubMed: 9183141]
- 24. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale. Arch 1989; 46:1006–1011
- 25. Lázaro L, Bargalló N, Castro-Fornieles J, Falcón C, Andrés S, Calvo R, Junqué C: Brain changes in children and adolescents with obsessive-compulsive disorder before and after treatment: A voxelbased morphometric MRI study. Psychiatry Res. - Neuroimaging 2009; 172:140–146
- 26. Ashburner J, Friston KJ: Voxel-based morphometry--the methods. Neuroimage 2000; 11:805–821 [PubMed: 10860804]
- Clarkson MJ, Cardoso MJ, Ridgway GR, Modat M, Leung KK, Rohrer JD, Fox NC, Ourselin S: A comparison of voxel and surface based cortical thickness estimation methods. Neuroimage 2011; 57:856–865 [PubMed: 21640841]
- Glasser MF, Coalson TS, Robinson EC, Hacker CD, Harwell J, Yacoub E, Ugurbil K, Andersson J, Beckmann CF, Jenkinson M, Smith SM, Van Essen DC: A multi-modal parcellation of human cerebral cortex. Nature 2016; 536:171–8 [PubMed: 27437579]
- 29. Fallucca E, MacMaster FP, Haddad J, Easter P, Dick R, May G, Stanley JA, Rix C, Rosenberg DR: Distinguishing Between Major Depressive Disorder and Obsessive-Compulsive Disorder in Children by Measuring Regional Cortical Thickness. 2011; 68:527–533

- 30. Kop ivová J, Horá ek J, Tint ra J, Praško J, Raszka M, Ibrahim I, Höschl C: Medial frontal and dorsal cortical morphometric abnormalities are related to obsessive-compulsive disorder. Neurosci. Lett. 2009; 464:62–66 [PubMed: 19666084]
- Boedhoe PSW, Schmaal L, Mataix-cols D, ENIGMA-OCD working group, Thompson PM, Stein D, van den Heuvel OA: Association and Causation in Brain Imaging : The Case of OCD -Response to McKay et al. Am. J. Psychiatry 2017; 174(6), 60–69 [PubMed: 27609241]
- 32. Gogtay N, Giedd JN, Lusk L, Hayashi KM, Greenstein D, Vaituzis a C, Nugent TF, Herman DH, Clasen LS, Toga AW, Rapoport JL, Thompson PM: Dynamic mapping of human cortical development during childhood through early adulthood. Proc. Natl. Acad. Sci. U. S. A. 2004; 101:8174–9 [PubMed: 15148381]
- Rakic P: Specification of Cerebral Cortical Areas. Science. 1988; 241:170–176 [PubMed: 3291116]
- Graybiel AM, Rauch SL: Toward a neurobiology of obsessive-compulsive disorder. Neuron 2000; 28:343–347 [PubMed: 11144344]
- Stern ER, Fitzgerald KD, Welsh RC, Abelson JL, Taylor SF: Resting-state functional connectivity between fronto-parietal and default mode networks in obsessive-compulsive disorder. PLoS One 2012; 7
- 36. Posner J, Song I, Lee S, Rodriguez CI, Moore H, Marsh R, Blair Simpson H: Increased functional connectivity between the default mode and salience networks in unmedicated adults with obsessive-compulsive disorder. Hum. Brain Mapp. 2017; 38:678–687 [PubMed: 27659299]
- 37. Zhang T, Wang J, Yang Y, Wu Q, Li B, Chen L, Yue Q, Tang H, Yan C, Lui S, Huang X, Chan RCK, Zang Y, He Y, Gong Q: Abnormal small-world architecture of top-down control networks in obsessive-compulsive disorder. J. Psychiatry Neurosci. 2011; 36:23–31 [PubMed: 20964957]
- O'Connor K, Aardema F: Fusion or confusion in obsessive compulsive disorder. Psychol. Rep. 2003; 93:227–232 [PubMed: 14563054]
- 39. Hoexter MQ, Duran DS, Alcante CCD, Dougherty DD, Shavitt RG, Lopes AC, Diniz JB, Deckersbach T, Batistuzzo MC, Bressan RA, Miguel EC, Busatto GF: Gray Matter Volumes in Obsessive-Compulsive Disorder Before and After Fluoxetine or Cognitive-Behavior Therapy : A Randomized Clinical Trial. Neuropsychopharmacology 2012; 37:734–745 [PubMed: 22030709]
- 40. Chen X, Liang S, Pu W, Song Y, Mwansisya TE, Yang Q, Liu H, Liu Z, Shan B, Xue Z: Reduced cortical thickness in right Heschl's gyrus associated with auditory verbal hallucinations severity in first-episode schizophrenia. BMC Psychiatry 2015; 15:152 [PubMed: 26149490]
- 41. Wierenga LM, Langen M, Oranje B, Durston S: Unique developmental trajectories of cortical thickness and surface area. Neuroimage 2014; 87, 120–126. [PubMed: 24246495]
- 42. Anderson BJ: Plasticity of gray matter volume: The cellular and synaptic plasticity that underlies volumetric change. Dev. Psychobiol. 2011; 53(5), 456–465. [PubMed: 21678393]
- Savalia NK, Agres PF, Chan MY, Feczko EJ, Kennedy KM, Wig GS: Motion-related artifacts in structural brain images revealed with independent estimates of in-scanner head motion. Hum. Brain Mapp. 2017; 38:472–492 [PubMed: 27634551]
- 44. van den Heuvel OA, Remijnse PL, Mataix-Cols D, Vrenken H, Groenewegen HJ, Uylings HBM, Van Balkom AJLM, Veltman DJ: The major symptom dimensions of obsessive-compulsive disorder are mediated by partially distinct neural systems. Brain 2009; 132:853–868 [PubMed: 18952675]
- Mataix-Cols D, Wooderson S, Lawrence N, Brammer MJ, Speckens A, Phillips ML: Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessivecompulsive disorder. Arch. Gen. Psychiatry 2004; 61:564–576 [PubMed: 15184236]
- Leckman JF, Denys D, Simpson HB, Mataix-Cols D, Hollander E, Saxena S, Miguel EC, Rauch SL, Goodman WK, Phillips KA, Stein DJ: Obsessive-compulsive disorder: A review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V. Depress. Anxiety 2010; 27:507–527 [PubMed: 20217853]
- 47. Anholt GE, Aderka IM, van Balkom AJLM, Smit JH, Schruers K, van der Wee NJA, Eikelenboom M, De Luca V, van Oppen P: Age of onset in obsessive-compulsive disorder: admixture analysis with a large sample. Psychol. Med. 2014; 44:185–194 [PubMed: 23517651]

Effect size d


# Adult OCD patients versus healthy controls: regional cortical thickness



#### Figure 1:

Mega-analysis effect sizes for regions that showed a significant (q<0.05) difference in cortical thickness between adult OCD patients and healthy controls. Negative effect sizes *d* (red) indicate cortical thinning in OCD compared to controls


# Pediatric OCD patients versus healthy controls: regional cortical thickness



#### Figure 2:

Mega-analysis effect sizes for regions that showed a significant (q<0.05) difference in cortical thickness between pediatric OCD patients and healthy controls. Negative effect sizes d (red) indicate cortical thinning in OCD compared to controls


# Adult medicated OCD patients versus healthy controls: regional cortical thickness



#### Figure 3:

Mega-analysis effect sizes for regions that showed a significant (q<0.05) difference in cortical thickness between adult medicated OCD patients and healthy controls. Negative effect sizes d (red) indicate cortical thinning in OCD compared to controls.

# Pediatric medicated OCD patients versus healthy controls: regional cortical surface area



#### Figure 4:

Mega-analysis effect sizes for regions that showed a significant (q<0.05) difference in cortical surface area between pediatric medicated OCD patients and healthy controls. Negative effect sizes d (red) indicate reduced cortical surface area in OCD compared to controls.

#### Table 1:

Mega-analytical demographics and clinical characteristics.

Characteristic	Adult OCD Patients (N=1498)		Adult Healthy Controls (N=1436)		Pediatric OCD Patients (N=407)		Pediatric Healthy Controls (N=324)	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Age (years)	32.1*	9.7	30.5*	9.7	13.8	2.5	13.6	2.6
OCD illness severity score <sup>a</sup>	24.4	6.9			21.4	7.3		
Age at onset of clinical symptoms (years)	19.8	9.1			10.6	3.1		
	Ν	%	Ν	%	Ν	%	Ν	%
Male	756	50.5	713	49.7	220	54.1	164	50.6
Medication use at time of scan	646	43,1			183	45.0		
Current comorbid anxiety disorder	224	15.0			132	32.4		
Current comorbid major depression diagnosis	167	11.1			29	7.1		
Current comorbid Tourette's ** Disorder	24	1.6			30	7.4		
Current comorbid ADHD **	13	0.9			42	10.3		
Current comorbid ASD **	0	0			5	1.2		
OCD symptom dimensions <sup>b</sup>								
Aggressive/checking	927	61.9			195	47.9		
Contamination/cleaning	791	52.8			172	42.3		
Symmetry/ordering	640	42.7			181	44.5		
Sexual/religious	487	32.5			92	22.6		
Hoarding	379	25.3			92	22.6		

 $^a\mathrm{As}$  measured with the Yale-Brown Obsessive Compulsive Scale (YBOCS) total score

 $^{b}$ As measured with the YBOCS symptom checklist

\* Statistically significant difference (t(2932)=-4.222, p<0.001)

\*\* not assessed in each sample

abbreviations: ADHD attention deficit hyperactivity disorder; ADS autism spectrum disorder